* Q2 beat with activity picking up * Pre-tax profit up by 13-16% for 2026-27e * 2025e-27e EV/EBIT of...
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
* '25e-'27e sales cut by 6-1% * Market softness persists, delaying customer decisions * Cost-cutting...
Redeye comments on Lipigon’s Q2 report. At the end of June, the company recruited the last patient t...
* Comps to become easier in '26e * Cutting '25e-'27e adj.
Redeye provides an initial take following the release of Corline’s Q2 2025 report.
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
* Q2 EBIT SEK -74m (vs. ABGSCe 103m) * EBIT negatively impacted by delay in Pome project timeline * ...
Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the ...
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye comments on Episurf’s rights issue of Units, which was oversubscribed to approximately 162.
We hosted NoHo Partners' CEO Jarno Suominen for a lunch meeting today in Helsinki.
Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Nettoomsättningen för det andra kvartalet uppgick till 6,6 MEURO (10,2), vilket motsvarade en minskn...
Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we r...
Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Crunchfish’s new go-to-market strategy for offline payments, splitting the solution into terminals f...
Cantargia’s Q2 report covers one of the most eventful periods in the company’s history.
Redeye provides an update following CLS’s Q2 2025 report.